3.0100 +0.17 (5.99%)
After hours: 6:40PM EDT
|Bid||2.7800 x 800|
|Ask||3.0000 x 900|
|Day's Range||2.4800 - 2.9700|
|52 Week Range||1.0300 - 4.8300|
|Beta (3Y Monthly)||1.32|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Jazz (JAZZ) acquires privately-held Cavion for a total consideration of $312.5 million including an upfront payment of $52.5 million and $260 million in potential clinical, regulatory and commercial milestones.
Jazz (JAZZ) acquired Redx Pharma's early stage pan-RAF inhibitor program for developing potential treatment for cancer with RAF and RAS mutations.
Jazz Pharmaceuticals' (JAZZ) recently approved sleep drug, Sunosi, receives schedule IV designation under controlled substance list from the Drug Enforcement Agency.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Even the best investor on earth makes unsuccessful investments. But it would be foolish to simply...
The Dublin-based company said it had a loss of 35 cents per share. The specialty pharmaceutical company posted revenue of $16.4 million in the period. The company's shares closed at $1.20. A year ago, ...
The Dublin-based company said it had a loss of $1.72 per share. The specialty pharmaceutical company posted revenue of $20.9 million in the period. For the year, the company reported a loss of $95.3 million, ...
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. Unfortunately, there are also plenty of examples of share prices Read More...
Jazz (JAZZ) announces that the FDA has extended the review period of its new drug application for sleep drug, solriamfetol, by three months to Mar 20, 2019.
The Dublin-based company said it had a loss of 43 cents per share. The specialty pharmaceutical company posted revenue of $19.8 million in the period. Avadel expects full-year revenue in the range of $90 ...